The European Society of Cardiology and the publishers regret that a table containing errors was published in these guidelines. Table 15 (page 2399 in the European Heart Journal and page 1390 in EP-Europace) should be replaced by the table below (the areas that have been corrected are identified by blue type).
ER = extended release formulations; N/A = not applicable.
aOnly in patients with non-permanent atrial fibrillation.
Also, Figure 9 (page 2400 in the European Heart Journal and page 1391 in EP-Europace) should have shown under ‘Inactive’ that the following rate control drugs are also allowed: β-blocker, diltiazem, and verapamil.
The authors wish to apologize that these errors were not identified earlier. The corrected table and figure appear in the online editions of the European Heart Journal and EP-Europace.